Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation

Amir Hossein Norooznezhad [a,b,]*, Fatemeh Norooznezhad [b]

[a] Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
[b] Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

Psoriasis is a chronic skin disease also affecting other sites such as joints. This disease highly depends on inflammation and angiogenesis as well as other pathways. At each step of the psoriasis molecular pathway, different inflammatory cytokines and angiogenic growth factors are involved such as hypoxia inducible factor-1 α (HIF-1 α), vascular endothelial growth factor (VEGF), matrix metalo proteinases (MMPs), basic fibroblast growth factor (bFGF), Angiopoitin-2, interleukin-8 (IL-8), IL-17, and IL-2. Beside the mentioned growth factors and cytokines, cellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) which play roles in both angiogenesis and inflammation are also involved in the pathogenesis. Cannabinoids are active compounds of Cannabina Sativa inducing their effects through cannabinoid receptors (CBs). JWH-133 is a synthetic cannabinoid with strong anti-angiogenic and anti-inflammatory activities. This agent is able to inhibit HIF-1 α, VEGF, MMPs, bFGF, IL-8, IL-17, and other mentioned cytokines and adhesion molecules both in vivo and in vitro. Altogether, authors suggest using this cannabinoid for treatment of psoriasis due to its potential in suppressing the two main steps of psoriatic pathogenesis. Of course complementary animal studies and human trials are still required.

© 2016 Elsevier Ltd. All rights reserved.

Introduction

Psoriasis (PS) is categorized as a skin and also joint disease which affects 2–4% of Caucasian population [1]. This disease is associated with hyperkeratotic plaques in different regions such as elbow, knee, and scalp. Other demonstrations include psoriatic arthritis (PSA) which is a kind of inflammatory synovitis presenting enthesitis and dactylitis leading to polyarthritis and oligoarthritis [1,2]. Histologically, psoriasis has been found to induce the following events: 1) Infiltration of inflammatory cells into the dermis and epidermis. 2) Epidermal hyperplasia and abnormal differentiation of keratinocytes. 3) Hyper-vascular culture in dermis [3–5]. Putting all together, inflammation and angiogenesis could be the two main targets of treatment for psoriasis.

Angiogenesis, the formation of new blood vessels from pre-existing ones, is the key mechanism in corneal neovascularization, tumor growth, rheumatoid arthritis and psoriasis [6–8]. This process is directed by angiogenic cytokines and growth factors such as hypoxia inducible factor-1 α (HIF-1 α), vascular endothelial growth factor (VEGF), matrix metalo proteinases (MMPs), basic fibroblast growth factor (bFGF), Angiopoitin-2, interleukin 8 (IL-8), IL-2 and IL-17. HIF-1α which is secreted under hypoxic situation triggers angiogenesis by inducing VEGF expression. VEGF is considered as a key role player in proliferation and migration of endothelial cells (ECs) finally leading to angiogenesis. Following VEGF activation MMPs (especially MMP-2 and MMP-9) also express and degrade basement membrane in order to facilitate migration of ECs. The mentioned cytokines such as ILs are involved in inflammatory and even angiogenesis processes [6,9–11].

Cannabinoids are known as active compounds of Cannabina Sativa with strong anti-inflammatory and anti-angiogenic activities [8]. These compounds are divided into different categories such as endocannabinoids [12] (physiologically produced in the body) and exocannabinoids (synthetics and plant derived CBNs) [13]. JWH-133, with an affinity to G-protein coupled cannabinoid receptor 2 (CB2) is a synthesized cannabinoid with various activities such as anti-angiogenic potential [8]. The CB2 is presented on the various types of cells such as ECs [14], T cells [15] and dendritic cells [16].

* Corresponding author at: Medical Biology Research Center, P.O. Box: 1568, Sorkheh Ligeh, Kermanshah, Iran.
E-mail address: Norooznezhad@gmail.com (A.H. Norooznezhad).

Hypothesis

Considering the proved role of cannabinoids in inhibition and suppression of inflammation and angiogenesis, authors of this study suggest JWH-133 for the treatment of PS. So far two papers hypothesized on possible role of CBNs in PS treatment, but no hypothesized angiogenic pathway is presented [17,18]. Although Namazi [17] stated anti-inflammatory potential of CBNs as a possible pathway but he just considered the role of TNF-α and IL-2. Derakhshande and Kazemi also presented the anti-inflammatory role of CBNs due to the cholinergic anti-inflammatory pathway [18].

Evaluation of hypothesis

Angiogenesis mainly consists of 3 major steps: proliferation, migration and tube formation of endothelial cells [19,20]. Each of these steps is affected by different cytokines and growth factors. As already mentioned, the hypoxia induced response molecule, HIF-1 α is increased in PS as a result of different conditions. This increase is mostly due to the secondary changes in nutrition and oxygen demand and supply following the cellular hyper-proliferation (of mostly keratinocytes) or prolongation of diffusion distance due to the plaque formation in dermis [10,21–23]. There is a positive correlation between HIF-1 α and VEGF levels in psoriatic patients' skin [23]. HIF-1 α is mostly responsible for the induction of VEGF expression [24]; although VEGF could express in other pathways as well [25]. VEGF is a key player of angiogenesis in most angiogenic dependent diseases. This factor causes endothelial cells proliferation and also induces the secretion of other angiogenic factors such as MMPs [26]. It has been showed that VEGF is significantly higher in PS patients' blood samples and psoriatic plaques [27–29]. Also, its plasma level could be directly associated with severity of PS considering the clinical presentations [30]. According to the studies, MMPs, especially MMP-2, are found to be highly elevated (up to two folds) in psoriatic patients. MMP-2 is a gelatinase A able to degrade gelatin types III, IV, V and XIV collagen, elastin and aggrecan which helps proliferated ECs to migrate to the proper site [31]. As Simonetti et al. showed, MMP-2 is significantly increased in PS skin tissue compared with normal controls. Also, this enzyme has a positive correlation with VEGF in these patients [23]. Different studies have shown that bFGF concentration is significantly higher in blood samples of psoriatic patients in comparison with controls [32,33]. One of the approved treatments for PS is Goeckerman's therapy. It has been destablished that both VEGF and bFGF serum levels are decreased following Goeckerman's therapy in 44 evaluated psoriatic patients compared with their pre-treatment conditions [32]. Ang-2, the other angiogenic factor accompanying VEGF, is able to destabilize the capillaries for initiation of angiogenesis by acting through its specific receptor Tie-2 [33]. Other than sensitizing ECs to TNF-α [34], Ang-2 could increase the expression of ICAM-1 and VCAM-1, two main intracellular molecules engaged in leukocytes infiltration to the tissues through the capillaries [6]. It has been demonstrated that both Ang-2 and Tie-2 are elevated in psoriatic skin in comparison with healthy situation. This expression was positively affected by over-expression of VEGF and bFGF as stimulators of ECs proliferation [33].

According to the data, infiltrated CD4+ cells into the skin are initiators of cutaneous inflammatory state which is characterized by production of different cytokines such as interferon γ (INF-γ), TNF-α and IL-2 [35,36]. TNF-α is responsible for VEGF, IL-8, bFGF expression through stimulation of ECs. Dendritic cells are able to induce VEGF expression via secretion of TNF-α in psoriasis which leads to angiogenesis [6]. IL-8 is a strong cytokine playing role in angiogenesis and inflammation. This cytokine is produced in dermal or epidermal layers by different cells such as ECs, T cells, fibroblasts and keratinocytes [37]. This cytokine is elevated in epidermis of psoriatic skin. IL-8 help lymphocytes to transmigrate through the capillaries to the tissue, which finally leads to the inflammation [38]. Also, this cytokine is able to induce keratinocytes hyper-proliferation as well as ECs. Besides, it can prevent the apoptosis through Bcl-2 pathway in ECs. More to mention IL-8 could induce production of both MMP-2 and MMP-9 in ECs [39]. Moreover, IL-8 and its receptor (IL-8 R) are significantly elevated in psoriatic patients' epidermis in comparison to healthy controls [40]. The other cytokine involved in PS pathogenesis is IL-17 which produces by T helper 17 cells [41]. This cytokine is able to induce angiogenesis through over-expression of other angiogenic factors such as VEGF [22].

So far, different treatments targeting each of the mentioned cytokines or growth factors are suggested and successfully used for treatment of psoriasis. According to Datta-Mitra's study on a PS patient with renal cancer which was treated by an anti-VEGF monoclonal anti-body (Bevacizumab®), a complete remission of PS and psoriatic arthritis was observed [42]. Additionally, in two cases with psoriasis who received Sunitinib (a tyrosine kinase inhibitor of VEGFR) an acceptable improvement in their condition was observed [43,44]. Monoclonal antibodies against TNF-α such as Infliximab® has been confirmed as a systemic treatment for adults' psoriasis by food and drug administration (FDA) in 2006 [45]. This anti-TNF-α antibody is able to inhibit VEGF, MMP-2, Ang-2 and Tie-2 expression which its anti-VEGF and anti-MMP-2 activities in psoriatic patients are proved [6]. Also Methotroxate another FDA approved (1972) agent for treatment of PS, is able to suppress VEGF in PS patients which is completely expected due to its anti-angiogenic activity [46]. Other treatments such as Cyclosporine (with anti-angiogenic and anti-inflammatory activity) and Neovastat® (an anti-angiogenic agent) are used in clinical trials for treatment of psoriasis successfully [6]. Also Secukinumab, Ixekizumab and Brodalumab, three monoclonal antibodies against IL-17 are introduced for PS treatment [41].

As mentioned earlier, PS close relationship with inflammation and angiogenesis has been proved by strong evidences [22]. It has been noted that vascular hyper-density in patients diagnosed with PS is an important step which precedes other steps such as epidermal hyperplasia [47].

Cannabinoids are known to have a critical role in suppressing and inhibiting angiogenesis and inflammation [48]. JWH-133 is able to inhibit angiogenesis both in vivo and in vitro [43,36] through suppression of ECs migration and proliferation [8]. Expression of HIF-1 α gene is 60% decreased after JWH-133 treatment in comparison to control. One of the known paths through which JWH-133 inhibits ECs proliferation is down-regulating VEGF expression. This inhibition occurs up to 50% and 80% for VEGF-A and VEGF-B genes, respectively. Also, this agent is able to decrease the production of VEGF receptor-2 which is the prominent VEGF receptor. A 50% decrease in Ang-2 expression was also detected as well as 60% suppression in Tie-1 [49]. As mentioned before, MMP-2 is a key factor in ECs migration which is strongly suppressed by JWH-133 [50]. Also, cannabinoids could inhibit TNF-α, INF-γ and IL-2 and IL-8 which are considered as key elements of both angiogenesis and inflammation in PS [51,52]. As Rossi et al. showed, JWH-133 could suppress IL-8, IL-1, TNF-α and INF-γ [53]. Furthermore, JWH-133 caused a 40% decrease in wild-type CD4+ T cell proliferation in comparison to controls [52]. Moreover, data show that JWH-133 is capable of suppressing TNF-α induced VCAM-1 and ICAM-1 expression on the surface of ECs [54]. Also JWH-133 could suppress dendritic cells function and maturation through TLR4 which is a main receptor for their function and maturation [51,52]. Moreover this CB2 selective agonist could down-regulate IL-17 expression in T helper cells [55]. Also CBNs are used

Fig. 1. Important angiogenic and inflammatory pathways of psoriasis pathogenesis which cannabinoids could inhibit them according to the current hypothesis. VEGF, vascular endothelial growth factor; MMP, matrix metalloproteinases; IL, Interleukin; HIF-1 α, hypoxia inducible factor-1 α; bFGF, basic fibroblast growth factor; ICAM-1, cellular adhesion molecule 1; VCAM-1, vascular cell adhesion molecule-1; Th 17 T helper lymphocyte.

for inhibition of keratinocytes proliferation which is very significant to PS [56]. In Fig. 1 some important pathways of PS pathogenesis which CBNs could inhibit/down-regulate them are introduced. Also we think that using a topical form of CBNs could be more acceptable in comparison to others such as oral or intra venous due to the possible less side effects.

To sum up, it seems that other than inhibiting keratinocytes proliferation, cannabinoids are also able to target two main pathways in PS pathogenesis: angiogenesis and inflammation. Considering these data authors of this study suggest JWH-133 as a possible treatment (oral or topical) for PS. However, further animal studies and human trials are necessary for this aim. We hope that the successful experiments and trials could introduce cannabinoids as a novel treatment for psoriasis in order to improve patients' quality of life and health.

Conflict of interest

Authors deny any conflict of interest related to this study.

Acknowledgment

References

[1] Diani M, Altomare G, Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun Rev 2015;14(4):286–92.
[2] Mortezavi M, Thiele R, Ritchlin C. The joint in psoriatic arthritis. Clin Exp Rheumatol 2015;33(5 Suppl 93):20.
[3] Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. The Lancet 2007;370(9583):263–71.
[4] Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445(7130):866–73.
[5] Boehncke W-H. Etiology and pathogenesis of psoriasis. Rheum Dis Clin North Am 2015;41(4):665–75.
[6] Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis: the new potential target for the therapy of psoriasis. Drug News Perspect 2008;21(2):97–105.
[7] Norooznezhad AH, Norooznezhad F, Ahmadi K. Next target of tranilast: inhibition of corneal neovascularization. Med Hypotheses 2014;82(6):700–2.
[8] Keshavarz M, Norooznezhad AH, Mansouri K, et al. Medical hypotheses and ideas. Irn J Med Hypotheses Ideas 2010;4:3.
[9] Leong TT, Fearon U, Veale DJ. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheumatol Rep 2005;7(4):325–9.
[10] Armstrong AW, Voyles SV, Armstrong EJ, et al. Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 2011;63(1):1–9.
[11] Creamer D, Sullivan D, Bicknell R, et al. Angiogenesis in psoriasis. Angiogenesis 2002;5(4):231–6.
[12] Costa M. The endocannabinoid system: a novel player in human placentation. Reprod Toxicol 2016;61:58–67.
[13] Telek A, Bíró T, Bodó E, et al. Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J 2007;21(13):3534–41.
[14] Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Springer; 2009.

[15] Robinson RH, Meissler JJ, Breslow-Deckman JM, et al. Cannabinoids inhibit T-cells via cannabinoid receptor 2 in an in vitro assay for graft rejection, the mixed lymphocyte reaction. J Neuroimmune Pharmacol 2013;8(5):1239–50.

[16] Do Y, McKallip RJ, Nagarkatti M, et al. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-κB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004;173(4):2373–82.

[17] Namazi M. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. J Eur Acad Dermatol Venereol 2005;19(3):319–22.

[18] Derakhshan N, Kazemi M. Cannabis for refractory psoriasis-high hopes for a novel treatment and a literature review. Curr Clin Pharmacol 2016.

[19] Folkman J. Angiogenesis. Annu Rev Med 2006;57:1–18.

[20] Hida K, Maishi N, Torii C, et al. Tumor angiogenesis—characteristics of tumor endothelial cells. Int J Clin Oncol 2016;21(2):206–12.

[21] Elias PM, Arbiser J, Brown BE, et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol 2008;173(3):689–99.

[22] Heidenreich R, Röcken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 2009;90(3):232–48.

[23] Simonetti O, Lucarini G, Goteri G, et al. VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immuno-histochemical study. Int J Immunopathol Pharmacol 2006;19(4):751–60.

[24] Subhani S, Vavilala DT, Mukherji M. HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. Angiogenesis 2016;1–17.

[25] Arany Z, Foo S-Y, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1&agr;. Nature 2008;451 (7181):1008–12.

[26] Plank M, Sleeman B. Tumour-induced angiogenesis: a review: review article. J Theor Med 2003;5(3–4):137–53.

[27] Young HS, Summers AM, Bhushan M, et al. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol 2004;122(1):209–15.

[28] Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180(3):1141–6.

[29] Crawshaw A, Griffiths C, Young H. Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs 2012;21(1):33–43.

[30] Bhushan M, McLaughlin B, Weiss J, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141(6):1054–60.

[31] Mezentsev A, Nikolaev A, Bruskin S. Matrix metalloproteinases and their role in psoriasis. Gene 2014;540(1):1–10.

[32] Andrys C, Borska L, Pohl D, et al. Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. Arch Dermatol Res 2007;298(10):479–83.

[33] Kuroda K, Sapadin A, Shoji T, et al. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001;116(5):713–20.

[34] Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-α and has a crucial role in the induction of inflammation. Nat Med 2006;12(2):235–9.

[35] Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9 (1):40–6.

[36] Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25(6):574–80.

[37] Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997;17(7):4015–23.

[38] Tuschil A, Lam C, Haslberger A, et al. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992;99(3):294–8.

[39] Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170(6):3369–76.

[40] Schulz BS, Michel G, Wagner S, et al. Increased expression of epidermal IL-8 receptor in psoriasis. Down-regulation by FK-506 in vitro. J Immunol 1993;151 (8):4399–406.

[41] Walsh S, Shear N. The Role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis. J Cutan Med Surg. 2016. 1203475416651605.

[42] Datta-Mitra A, Riar NK, Raychaudhuri SP. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol 2014;59(6):632.

[43] Narayanan S, Callis-Duffin K, Batten J, et al. Improvement of psoriasis during sunitinib therapy for renal cell carcinoma. Am J Med Sci 2010;339(6):580–1.

[44] Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007;149(3):103–6.

[45] Gall JS, Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics 2008;2(1):115.

[46] Shaker OG, Khairallah M, Rasheed HM, et al. Antiangiogenic effect of methotrexate and PUVA on psoriasis. Cell Biochem Biophys 2013;67 (2):735–42.

[47] Varricchi G, Granata F, Loffredo S, et al. Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 2015;73(1):144–53.

[48] Norooznezhad AH, Norooznezhad F. How could cannabinoids be effective in multiple evanescent white dot syndrome? A hypothesis. J Rep Pharm Sci 2016;5(1):49–52.

[49] Blázquez C, González-Feria L, Álvarez L, et al. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004;64 (16):5617–23.

[50] Blázquez C, Salazar M, Carracedo A, et al. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 2008;68(6):1945–52.

[51] Xu H, Cheng CL, Chen M, et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 2007;82(3):532–41.

[52] Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007;13(4):492–7.

[53] Rossi F, Bernardo ME, Bellini G, et al. The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties. PLoS ONE 2013;8(11):e80022.

[54] Rajesh M, Mukhopadhyay P, Bátkai S, et al. CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007;293(4):H2210–8.

[55] Guillot A, Hamdaoui N, Bizy A, et al. Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver. Hepatology 2014;59(1):296–306.

[56] Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 2007;45 (2):87–92.